Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report
Issued Date
2022-07-01
Resource Type
ISSN
00411345
eISSN
18732623
Scopus ID
2-s2.0-85133808907
Pubmed ID
35810019
Journal Title
Transplantation Proceedings
Volume
54
Issue
6
Start Page
1675
End Page
1678
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transplantation Proceedings Vol.54 No.6 (2022) , 1675-1678
Suggested Citation
Getsuwan S., Tanpowpong P., Hongeng S., Anurathapan U., Pakakasama S., Treepongkaruna S. Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report. Transplantation Proceedings Vol.54 No.6 (2022) , 1675-1678. 1678. doi:10.1016/j.transproceed.2022.05.003 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85750
Title
Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report
Author's Affiliation
Other Contributor(s)
Abstract
Background: Eosinophilic gastrointestinal disorders (EGIDs) are well-documented entities in pediatric solid organ transplantation. However, the diseases are rare after bone marrow transplantation (BMT). Case presentation: We present an adolescent male with hemoglobin E-β-thalassemia who underwent BMT and developed chronic graft-versus-host disease (GVHD) mimicking EGIDs. Initially, the patient presented with a presumed diagnosis of eosinophilic gastroenteritis (subserosal type) and received corticosteroids for 12 weeks. Six months after corticosteroids cessation, he again developed abdominal pain, treated with corticosteroids, azathioprine, and a six-food elimination diet. Still, he later had similar symptoms with persistent hypereosinophilia. The patient was subsequently diagnosed with chronic GVHD after excluding various potential causes. Ruxolitinib also led to significant clinical improvement and the disappearance of eosinophilia. Conclusion: The differential diagnosis of chronic GVHD should be a concern in BMT recipients with persistent gastrointestinal symptoms and eosinophilia. Ruxolitinib may be a treatment option in children with a steroid-refractory disease.